Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Petra Došenović Bonča) .

1 - 2 / 2
First pagePrevious page1Next pageLast page
1.
Ocena finančnega bremena pri bolnikih z rakom v Sloveniji
Marjeta Skubic, Katja Vöröš, Andraž Perhavec, Mojca Bavdaž, Petra Došenović Bonča, Tjaša Redek, Ivica Ratoša, Helena Barbara Zobec Logar, 2024, original scientific article

Abstract: Izhodišče: Finančna toksičnost (FT) predstavlja vse objektivne finančne posledice in subjektivne finančne skrbi, ki se pojavljajo pri bolnikih z rakom in njihovih svojcih zaradi bolezni in zdravljenja. Finančno breme, ki ga imajo slovenski bolniki z rakom, pred našo raziskavo še ni bilo opredeljeno, prav tako ni bil poznan vpliv FT na kakovost življenja (QoL).Namen: Cilj raziskave je bila ocena FT pri bolnikih z rakom v Sloveniji, njen vpliv na QoL bolnikov in preizkus dosedanjih inštrumentov za oceno FT in QoL.Metode: Za merjenje FT smo uporabili anketno metodologijo. Razvili smo lasten vprašalnik za oceno FT in uporabili mednaro-dno validirana vprašalnika FACIT-COST in EORTC QLQ-C30. Raziskava je bila prospektivna in presečna, potekala je na Onkolo-škem inštitutu Ljubljana od junija do oktobra 2023. Rezultati: Analizirali smo 590 veljavnih anket. Na podlagi vprašalnika FACIT-COST smo ugotovili, da večina anketiranih bolnikov (53,7 %) nima FT, pri 42,9 % anketiranih bolnikov pa je bila ta večinoma blaga do zmerna. Nizko FT med slovenski-mi bolniki z rakom smo potrdili tudi z vprašalnikom EORTC QLQ-C30 in lastnim vprašalnikom. Večina bolnikov (85,1 %) je ocenila, da zaradi bolezni in zdravljenja niso imeli večjih stroškov. Na podlagi kazalnika finančnega bremena FACIT-COST in EORTC QLQ-C30 smo ugotovili, da so rizične skupine za večjo FT predvsem bolniki z nižjim neto dohodkom na gospodinjstvo (p ≤0,001), mlajši bolniki (p < 0,001), bolniki z rakom dojk (p = 0,016), zaposleni (p < 0,001), pa tudi bolniki na aktivnem onkološkem zdravljenju (p = 0,039). Pri lastnem vprašalniku so se za statistično pomembne pokazali še nižja stopnja izobrazbe (p ≤ 0,001), pode-želsko okolje (p = 0,033) in vrsta zdravstvenega zavarovanja (p = 0,006). Vpliv veroizpovedi na FT na podlagi lastnega vprašalnika ni povezan z večjo FT, kot je to razvidno iz vprašalnikov FACI-T-COST in EORTC QLQ-C30. Potrdili smo tudi vpliv nižjega dohodka na slabšo QoL, ostali parametri, ki vplivajo na QoL, pa so še: zelo nizka ali zelo visoka stopnja izobrazbe, rak glave in vratu in aktivnost onkološkega zdravljenja.Zaključki: V Sloveniji večina bolnikov z rakom ne občuti FT, v 42,9 % pa je ta blaga do zmerna. FT je statistično značilno povezana z višino dohodka, starostjo, vrsto raka, zaposlitvenim statusom, aktivnostjo onkološkega zdravljenja, pa tudi s stopnjo izobrazbe, podeželskim okoljem in vrsto zdravstvenega zavarova-nja. Večja FT je povezana s slabšo QoL. Ta je povezana prav tako z višino dohodka, stopnjo izobrazbe, vrsto raka in aktivnostjo onkološkega zdravljenja.
Keywords: finančno breme, kakovost življenja, breme raka
Published in DiRROS: 26.07.2024; Views: 375; Downloads: 169
.pdf Full text (5,00 MB)

2.
Mortality, seasonal variation, and susceptibility to acute exacerbation of COPD in the pandemic year : a nationwide population study
Irena Šarc, Aleša Lotrič Dolinar, Tina Morgan, Jože Sambt, Kristina Ziherl, Dalibor Gavrić, Julij Šelb, Aleš Rozman, Petra Došenović Bonča, 2022, original scientific article

Abstract: Background: Previous studies have suggested that the coronavirus disease 2019 (COVID-19) pandemic was associated with a decreased rate of acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Data on how the COVID-19 pandemic has influenced mortality, seasonality of, and susceptibility to AECOPD in the chronic obstructive pulmonary disease (COPD) population is scarce. Methods: We conducted a national population-based retrospective study using data from the Health Insurance Institute of Slovenia from 2015 to February 2021, with 2015–2019 as the reference. We extracted patient and healthcare data for AECOPD, dividing AECOPD into severe, resulting in hospitalisation, and moderate, requiring outpatient care. The national COPD population was generated based on dispensed prescriptions of inhalation therapies, and moderate AECOPD events were analysed based on dispensed AECOPD medications. We extracted data on all-cause and non-COVID mortality. Results: The numbers of severe and moderate AECOPD were reduced by 48% and 34%, respectively, in 2020. In the pandemic year, the seasonality of AECOPD was reversed, with a 1.5-fold higher number of severe AECOPD in summer compared to winter. The proportion of frequent exacerbators (2 AECOPD hospitalisations per year) was reduced by 9% in 2020, with a 30% reduction in repeated severe AECOPD in frequent exacerbators and a 34% reduction in persistent frequent exacerbators (2 AECOPD hospitalisations per year for 2 consecutive years) from 2019. The risk of two or more moderate AECOPD decreased by 43% in 2020. In the multivariate model, pandemic year follow-up was the only independent factor associated with a decreased risk for severe AECOPD (hazard ratio [HR]: 0.71; 95% confidence interval [CI]: 0.61–0.84; p < 0.0001). In 2020, non-COVID mortality decreased (−15%) and no excessive mortality was observed in the COPD population. Conclusion: In the pandemic year, we found decreased susceptibility to AECOPD across severity spectrum of COPD, reversed seasonal distribution of severe AECOPD and decreased non-COVID mortality in the COPD population.
Keywords: chronic obstructive pulmonary disease -- mortality, pandemics, seasons, exacerbation, acute exacerbation, seasonal variations, population study
Published in DiRROS: 14.03.2022; Views: 971; Downloads: 518
URL Link to file
This document has many files! More...

Search done in 0.09 sec.
Back to top